Matrix Metalloproteinases and Kidney Disease
Author Information
Author(s): Michael Zeisberg, Mona Khurana, Velidi H Rao, Dominic Cosgrove, Jean-Philippe Rougier, Michelle C Werner, Charles F Shield III, Zena Werb, Raghu Kalluri
Primary Institution: Beth Israel Deaconess Medical Center and Harvard Medical School
Hypothesis
MMPs with overlapping substrate specificities could compensate for each other's absence in the setting of GBM-degradation.
Conclusion
Preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection.
Supporting Evidence
- Increased MMP expression was observed in kidneys from patients with end-stage renal failure due to X-linked Alport syndrome.
- Pharmacological ablation of MMP activity before the onset of proteinuria led to significant attenuation in disease progression.
- Inhibition of MMPs after the onset of proteinuria accelerated disease progression.
Takeaway
This study shows that certain enzymes can help or hurt kidney health, depending on when they are blocked. Blocking them early can help, but blocking them later can make things worse.
Methodology
The study used a mouse model of Alport syndrome and human kidney samples to evaluate the role of MMPs in kidney disease progression.
Limitations
The study primarily focused on a mouse model, which may not fully replicate human disease.
Participant Demographics
The study included male patients with X-linked Alport syndrome and age-matched control mice.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website